Mostrar el registro sencillo del ítem

dc.contributor.authorTristán, Ana Isabel
dc.contributor.authorCaba Pérez, Octavio 
dc.contributor.authorJiménez Luna, Cristina 
dc.contributor.authorMelguizo Alonso, Consolación 
dc.contributor.authorPrados Salazar, José Carlos 
dc.date.accessioned2023-05-30T12:27:11Z
dc.date.available2023-05-30T12:27:11Z
dc.date.issued2023
dc.identifier.citationTristán AI, González-Flores E, Salmer on AM, et al. Serum nuclear magnetic resonance metabolomics analysis of human metastatic colorectal cancer: Biomarkers and pathway analysis. NMR in Biomedicine. 2023;e4935. [doi:10.1002/nbm.4935]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/82033
dc.descriptionJunta de Andalucía, Grant/Award Numbers: 102C2000004, UAL2020-AGR-B1781, P20_01041; Gobierno de España, Grant/Award Numbers: PDC2021– 121248-I00, PLEC2021–007774; Instituto de Salud Carlos III (ISCIII), Grant/Award Number: PI19/01478; CTS-107 and FQM-376 groupses_ES
dc.description.abstractWe describe the use of nuclear magnetic resonance metabolomics to analyze blood serum samples from healthy individuals (n = 26) and those with metastatic colorectal cancer (CRC; n = 57). The assessment, employing both linear and nonlinear multivari- ate data analysis techniques, revealed specific metabolite changes associated with metastatic CRC, including increased levels of lactate, glutamate, and pyruvate, and decreased levels of certain amino acids and total fatty acids. Biomarker ratios such as glutamate-to-glutamine and pyruvate-to-alanine were also found to be related to CRC. The study also found that glutamate was linked to progression-free survival and that both glutamate and 3-hydroxybutyrate were risk factors for metastatic CRC. Additionally, gas chromatography coupled to flame-ionization detection was utilized to analyze the fatty acid profile and pathway analysis was performed on the profiled metabolites to understand the metabolic processes involved in CRC. A correlation was also found between the presence of certain metabolites in the blood of CRC patients and certain clinical features.es_ES
dc.description.sponsorshipJunta de Andalucia 102C2000004, UAL2020-AGR-B1781, P20_01041es_ES
dc.description.sponsorshipGobierno de España MCIN/AEI/10.13039/501100011033/Unión Europea “Next GenerationEU”/PRTR (PDC2021–121248-I00 and PLEC2021–007774)es_ES
dc.description.sponsorshipInstituto de Salud Carlos III (ISCIII) (PI19/01478) (FEDER)es_ES
dc.description.sponsorshipCTS-107es_ES
dc.description.sponsorshipFQM-376es_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleSerum nuclear magnetic resonance metabolomics analysis of human metastatic colorectal cancer: Biomarkers and pathway analysises_ES
dc.typejournal articlees_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/Next GenerationEU/PRTR (PDC2021–121248-I00 and PLEC2021–007774)es_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1002/nbm.4935
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional